Neurology
PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
August 7, 2025Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
August 6, 2025Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …
Lilly’s drug for early Alzheimer’s shows promising results
August 6, 2025Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
July 30, 2025Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …
Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company
July 29, 2025Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions
Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …
Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate
July 28, 2025Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis
Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
July 18, 2025Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
July 16, 2025Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani
July 10, 2025Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology
Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …
Carthera receives EMA endorsement for orphan medical device status of SonoCloud
July 2, 2025Medical Communications, Research and Development Brain disorders, Breakthough Device Designation, CE marking, Carthera, Devices, European Medicines Agency (EMA), Food and Drug Administration, Forfait Innovation Status, Neurology, Orphan Medical Device Status, ultrasound imaging
French biotech company Carthera has announced that its SonoCloud system has been granted orphan medical device status by the European …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
July 1, 2025Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board
June 25, 2025Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board
PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
